MIL:ARBS

Arterra Bioscience · MIL · Healthcare · EUR · FY for 2025

Figures on this page computed 2026-11-08 12:44 UTC

Last close

n/aEUR

Market data

10.1xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
43.1%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
33.1%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
EUR
- Computed from the filing for 2025
- Computed from the filing for 2025
4.2%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
EUR
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

All from 100

lens 2 of 9

Sales

226

2017-12-31 to 2025-12-31100 at the start226

Sales: 100.00 on 2017-12-31 to 226.41 on 2025-12-31, up 126%.

Profit

269

2017-12-31 to 2025-12-31100 at the start269

Profit: 100.00 on 2017-12-31 to 269.21 on 2025-12-31, up 169%.

Shares in issue

102

2017-12-31 to 2025-12-31100 at the start102

Shares in issue: 100.00 on 2017-12-31 to 101.74 on 2025-12-31, up 2%.

Sales is at 226, Profit is at 269, Shares in issue is at 102, against 100 in 2017.

Sales is at 226, Profit is at 269, Shares in issue is at 102, against 100 in 2017.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales, where the first year is 100226
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Profit, where the first year is 100269
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR
Shares in issue, where the first year is 100102
Source
computed
Statement
income
Fiscal year
2025
Reported in
EUR